CELLULAR THERAPY
Selected solid-tumor CAR-T access.
Current clinical focus: CLDN18.2-positive advanced gastric / gastroesophageal junction cancer in appropriate later-line settings.
Pathology and biomarker relevance
CLDN18.2 status and HER2-negative context are central to determining relevance for this pathway.
Prior therapies and disease status
Prior systemic therapy, current imaging and disease status inform whether this later-line pathway may be appropriate.
Regulatory context
Regulatory approval does not by itself establish individual patient eligibility, center availability or a Vialen treatment pathway.
In China, satricabtagene autoleucel (satri-cel) was approved in June 2026 for patients with CLDN18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma after failure of at least two prior lines of therapy. It is the first CAR-T therapy approved for the treatment of a solid tumor. Other solid-tumor CAR-T approaches remain investigational or program-specific.
Center-specific review
Clinical suitability for this pathway is determined by the treating center against its current program criteria.
Related Questions
If a case is already close to this pathway, these pages answer the specific question a family or physician usually has next.
Could satri-cel be worth a formal review for my gastric / GEJ cancer? →
A progression, biomarker and local-option decision gate before travel or treatment commitment.
Is the U.S. CT041 / satri-cel trial still recruiting? →
What it means that the U.S. trial is active but not recruiting.
What does my CLDN18.2 test result actually show? →
Why the exact percentage matters more than positive or negative.
What should I know about satri-cel treatment cost and episode economics? →
What a complete treatment episode includes beyond the product price.